Job Opportunities API

The Public Ledger of Openings

← Back to the ledger

Director/Senior Director, In Vivo Pharmacology

rezotx
Companyrezotx
CategoryHealthcare
LocationSan Francisco
RemoteOn-site (inferred)
EmploymentFull-time
LevelDirector
SalaryNot stated by the employer
Posted15 May 2026
Last verified10 Aug 2026
SourceEmployer ATS (lever)
Applications are handled by the employer, not by us.Apply on the employer's site →
Description
About Rezo Therapeutics Rezo is a different kind of biopharma company. Our mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it.     We are leveraging a unique integrated approach, combining capabilities in genetics, proteomics, structural biology and AI to generate deep biological insights and novel therapeutic approaches.   Located in San Francisco’s vibrant Mission Bay neighborhood, Rezo is in close proximity to UCSF, numerous urban amenities, and outdoor recreational opportunities. We recognize that realizing our mission depends as much on our people as it does on our science and are building a workplace that fosters collaboration, respect, and diversity where contributing to your team’s success is valued as highly as individual achievements.  If you’re passionate about team science and breaking down barriers to progress in drug development, please consider joining us!  The Opportunity Rezo is seeking an experienced Director/Senior Director of In Vivo Pharmacology to lead the strategy, design, execution, and interpretation of in vivo pharmacology studies across our oncology portfolio. The successful candidate will bring deep expertise in oncology models, PK/PD-driven study design, translational pharmacology, and cross-functional drug discovery. They will work closely with biology, medicinal chemistry, DMPK, and external CRO partners to generate robust, decision-driving in vivo data packages. This is an opportunity to build and shape the in vivo pharmacology function at a growing oncology biotech, with direct impact on program strategy and portfolio progression.